Client of a consultant lobbyist
Organon Canada Inc.
- Meetings this Parliament
- 1
- With MPs
- 1
- Since Nov 2021
- 3
- Active registrations
- 0
Most recent reported meeting: Nov 25, 2025.
Lobbying by Organon Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Organon Canada Inc. has no active registration. Organizations must register once paid lobbying passes the legal threshold, and their registration ends when it stops.
Reported meetings
Spreadsheet-
Reported by Francois de Le Rue · Consultant
- Tom Kmiec · Member of Parliament
- Louis Plamondon · Député
- Pavlo Kucher · Director of Parliamentary Affairs & Operations, House of Commons
- Krista Ann Ross · Senator, Senate of Canada
and 5 moreShow fewer
- Mary Robinson · Sénatrice, Senate of Canada
- Vincent Desmarais · Directeur des communications, House of Commons
- Adrian Deleanu · Intern, House of Commons
- Mehek Noorani · Director of Parliamentary Affairs, Senate of Canada
- Kara Emberson · Director of Parliamentary Affairs, Health Canada (HC)
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities. Read more
To recommend policies that will attract increased investment in the pharmaceutical and well being industry, such as on policies, research programs and policies and the Innovation Agenda.
To actively promote the enhancement of publicly funded women’s health initiatives/programs.
Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs.
To actively promote the value of the pharmaceutical industry for Canada's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in Canada.
-
Reported by Francois de Le Rue · Consultant
- Kaitlyn Staines · Conseillère régionale, Atlantique et Assistante des opérations, Women and Gender Equality (WAGE)
Economic Development
-
Reported by Francois de Le Rue · Consultant
- Trinity Noble · Conseiller, House of Commons
Economic Development
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.